razoxane has been researched along with fluorouracil in 38 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (39.47) | 18.7374 |
| 1990's | 17 (44.74) | 18.2507 |
| 2000's | 5 (13.16) | 29.6817 |
| 2010's | 1 (2.63) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Moertel, CG | 1 |
| Boggust, WA; McGauley, H | 1 |
| Bendel, V; Hassenstein, E; Renner, K; Wolf, R | 1 |
| Dorr, RT | 1 |
| Blum, RH; Green, MD; Speyer, JL; Walsh, C | 1 |
| Blum, RH; Green, MD; Hochester, H; Kramer, E; Meyers, M; Rey, M; Sanger, J; Speyer, JL; Wernz, JC; Zeleniuch-Jacquotte, A | 1 |
| Carchman, RA; Carter, WH | 1 |
| Dubin, N; Ferrans, V; Green, MD; Kramer, E; Rey, M; Sanger, J; Speyer, JL; Stecy, P; Ward, C; Zeleniuch-Jacquotte, A | 1 |
| Hahn, RG; Moertel, CG; O'Connell, MJ; Rubin, J; Schutt, AJ; Scott, M | 1 |
| Green, MD | 1 |
| Ashford, RF; Bakowski, M; Evans, M; Hellman, K; Jones, R; Lambert, J; Newton, K; Peters, N; Phillips, R; Smith, BJ | 1 |
| Engstrom, PF; Klaassen, DJ; MacIntyre, JM; Mittelman, A | 1 |
| Cullinan, S; Everson, L; Gerstner, J; Krook, J; Laurie, J; McCormack, G; Schutt, A; Scott, M; Shreck, R; Windschitl, H | 1 |
| Campbell, ED; Carter, WH; Stablein, DM; Wampler, GL | 1 |
| Kaplan, BH; Lanham, R; Vogl, SE | 1 |
| Cassell, PC; Ellis, H; Evans, MG; Gilbert, JM; Hellmann, K; Stoodley, BJ; Wastell, C | 1 |
| Cullinan, SA; Everson, LK; Krook, JE; Scott, M; Windschitl, HE | 1 |
| Sherlock, D; Ward, A | 1 |
| Hochster, H; Speyer, J; Wasserheit, C | 1 |
| Bosnjak, S; Jelić, S; Kreacić, M; Milanović, N; Nesković-Konstantinović, Z; Radulović, S; Ristović, Z; Vuletić, L | 1 |
| Armand, JP; de Forni, M | 1 |
| Bagdasarov, IuB; Min'kov, ED; Niu-Tian-de, GB; Odzharova, AA; Shkhvatsabaia, LV; Zaĭtseva, TI | 1 |
| Garin, AM; Lichinitser, MR; Min'kov, ED; Nakhalova, TA; Odzharova, AA; Vyshinskaia, GV | 1 |
| Bastholt, L; Gjedde, SB; Jakobsen, P; Mirza, MR; Mouridsen, HT; Rose, C; Sørensen, B | 2 |
| Jurga, L; Misurová, E; Vancík, J | 1 |
| Garin, AM; Lichinitser, MP; Min'kov, ED; Nakhalova, TA; Odzharova, AA; Vyshinskaia, GV | 1 |
| Bianchine, JR; Desai, A; Ewer, MS; Gams, RA; Gerber, MC; Jones, SE; Mittelman, A; Pendergrass, K; Reddy, S; Speyer, J; Spicer, D; Swain, SM; Velez-Garcia, E; Vogel, C; Wadler, S; Weisberg, S; Whaley, FS; York, M | 1 |
| Bianchine, JR; Ewer, MS; Gams, RA; Gerber, MC; Swain, SM; Whaley, FS | 1 |
| Lemez, P | 1 |
| Bos, AM; van der Graaf, WT; Willemse, PH | 1 |
| Arundell, E; Bates, M; Lieu, D; Tonkin, K; Williamson, T; Zagari, M | 1 |
| Guchelaar, HJ; Richel, DJ; Schimmel, KJ; van den Brink, RB | 1 |
| Brouwer, RE; Uges, JW; Vollaard, AM; Wilms, EB | 1 |
| Cunningham, D; Hawkes, EA; Okines, AF; Plummer, C | 1 |
4 review(s) available for razoxane and fluorouracil
| Article | Year |
|---|---|
Chemoprotectants for cancer chemotherapy.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Asparaginase; Cisplatin; Cyclophosphamide; Fluorouracil; Humans; Ifosfamide; Leucovorin; Mesna; Methotrexate; Neoplasms; Razoxane; Sulfhydryl Compounds; Uridine | 1991 |
Cardiotoxicity and cardioprotection during chemotherapy.
Topics: Adult; Anthracyclines; Antineoplastic Agents; Cardiovascular Agents; Child; Clinical Trials as Topic; Cyclophosphamide; Female; Fluorouracil; Heart; Heart Diseases; Humans; Interleukin-2; Male; Neoplasms; Paclitaxel; Razoxane; Retrospective Studies; Survivors | 1995 |
Cardiotoxicity of chemotherapy.
Topics: Alkylating Agents; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Fluorouracil; Heart Diseases; Humans; Mice; Mitoxantrone; Neoplasms; Paclitaxel; Prospective Studies; Rabbits; Rats; Razoxane | 1994 |
Cardiotoxicity of cytotoxic drugs.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antioxidants; Biomarkers; Calcium Channels; Cardiomyopathies; Cardiotonic Agents; Chelating Agents; Cisplatin; Cyclophosphamide; Fluorouracil; Heart; Humans; Ifosfamide; Oxidative Stress; Razoxane; Risk Factors; Trastuzumab | 2004 |
16 trial(s) available for razoxane and fluorouracil
| Article | Year |
|---|---|
Modulation of the effect of anthracycline efficacy and toxicity by ICRF-187.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Synergism; Fluorouracil; Humans; Piperazines; Randomized Controlled Trials as Topic; Razoxane | 1990 |
A prospective randomized trial of ICRF-187 for prevention of cumulative doxorubicin-induced cardiac toxicity in women with breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiomyopathies; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Heart; Humans; Prospective Studies; Razoxane | 1990 |
Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Tolerance; Female; Fluorouracil; Heart; Heart Failure; Humans; Middle Aged; Myocardium; Piperazines; Radionuclide Imaging; Random Allocation; Razoxane; Stroke Volume | 1988 |
A randomized clinical trial of combination chemotherapy in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Prospective Studies; Random Allocation; Razoxane; Rectal Neoplasms; Semustine; Time Factors; Triazines; Vincristine | 1987 |
A trial of high-dose 5-fluorouracil with razoxane or adriamycin in the treatment of advanced adenocarcinoma of the gastrointestinal tract.
Topics: Adenocarcinoma; Clinical Trials as Topic; Colonic Neoplasms; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Fluorouracil; Gastrointestinal Neoplasms; Humans; Pancreatic Neoplasms; Piperazines; Prognosis; Razoxane; Rectal Neoplasms; Stomach Neoplasms | 1983 |
Chemotherapy of advanced colorectal carcinoma: fluorouracil alone vs. two drug combinations using fluorouracil, hydroxyurea, semustine, dacarbazine, razoxane, and mitomycin. A phase III trial by the Eastern Cooperative Oncology Group (EST: 1278).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; Drug Administration Schedule; Female; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; Humans; Hydroxyurea; Male; Middle Aged; Mitomycins; Random Allocation; Razoxane; Rectal Neoplasms; Semustine; Time Factors | 1984 |
Randomized phase II studies in advanced colorectal carcinoma: a North Central Cancer Treatment Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea; Drug Evaluation; Female; Fluorouracil; Humans; Leukopenia; Male; Middle Aged; Nausea; Random Allocation; Razoxane; Rectal Neoplasms; Semustine; Stomatitis; Thrombocytopenia; Triazines; Vomiting | 1983 |
Combination chemotherapy of advanced colorectal cancer with triazinate and ICRF-159 after failure of 5-Fluorouracil.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Diarrhea; Drug Administration Schedule; Drug Therapy, Combination; Fluorouracil; Folic Acid Antagonists; Humans; Leukopenia; Nausea; Piperazines; Razoxane; Rectal Neoplasms; Thrombocytopenia; Triazines | 1980 |
A controlled prospective trial of adjuvant razoxane in resectable colorectal cancer.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Fluorouracil; Humans; Piperazines; Razoxane; Rectal Neoplasms; Recurrence; Semustine; Vincristine | 1981 |
[An evaluation of the cardioprotective action of the preparation ICRF-187 (Cardioxane) during the treatment of breast cancer with large doses of adriamycin].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiomyopathies; Cardiovascular Agents; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Heart; Humans; Middle Aged; Myocardial Contraction; Razoxane; Time Factors | 1994 |
The pharmacokinetics of high-dose epirubicin and of the cardioprotector ADR-529 given together with cyclophosphamide, 5-fluorouracil, and tamoxifen in metastatic breast-cancer patients.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chromatography, High Pressure Liquid; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Fluorouracil; Heart Diseases; Humans; Middle Aged; Neoplasm Metastasis; Razoxane; Tamoxifen | 1994 |
The cardioprotector ADR-529 and high-dose epirubicin given in combination with cyclophosphamide, 5-fluorouracil, and tamoxifen: a phase I study in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Razoxane; Tamoxifen | 1994 |
Amelioration of doxorubicin cardiotoxicity by the bispiperazinedione ICRF-187 in women with advanced breast cancer: a preliminary report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Heart; Humans; Infusions, Intravenous; Middle Aged; Razoxane | 1993 |
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Agents; Cyclophosphamide; Disease-Free Survival; Double-Blind Method; Doxorubicin; Female; Fluorouracil; Heart Failure; Humans; Prospective Studies; Razoxane; Risk Factors; Survival Analysis; Treatment Outcome | 1997 |
Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Agents; Cyclophosphamide; Disease-Free Survival; Double-Blind Method; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Heart Failure; Humans; Middle Aged; Prospective Studies; Razoxane; Treatment Outcome | 1997 |
Dexrazoxane cardioprotection for patients receiving FAC chemotherapy: a pharmacoeconomic evaluation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Agents; Cost-Benefit Analysis; Cyclophosphamide; Decision Support Techniques; Doxorubicin; Economics, Pharmaceutical; Female; Fluorouracil; Health Care Costs; Heart; Heart Diseases; Humans; Markov Chains; Middle Aged; Models, Economic; Neoplasm Staging; Razoxane; Sensitivity and Specificity | 1996 |
18 other study(ies) available for razoxane and fluorouracil
| Article | Year |
|---|---|
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Chemotherapy of gastrointestinal cancer.
Topics: Doxorubicin; Floxuridine; Fluorouracil; Gastrointestinal Neoplasms; Humans; Liver Neoplasms; Mitomycins; Nitrosourea Compounds; Pancreatic Neoplasms; Razoxane; Streptozocin | 1976 |
Inhibition of collagen peptidase in HeLa cells and human tumours by compounds including drugs used in cancer therapy.
Topics: Antineoplastic Agents; Aprotinin; Collagen; Cyclophosphamide; Edetic Acid; Fluorouracil; HeLa Cells; Humans; Microbial Collagenase; Neoplasms; Phenanthrolines; Razoxane; Thiotepa | 1978 |
[Animal experiments on the toxicity of tumoricidal agents].
Topics: Animals; Bone Marrow; Female; Fluorouracil; Leukocyte Count; Mice; Piperazines; Platelet Count; Radiation Injuries, Experimental; Razoxane | 1978 |
Mathematical and biostatistical methods for designing and analyzing complex chemical interactions.
Topics: Altretamine; Animals; Cisplatin; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Mice; Mice, Inbred Strains; Models, Chemical; Razoxane; Sister Chromatid Exchange; Statistics as Topic | 1988 |
Rationale and strategy for prevention of anthracycline cardiotoxicity with the bisdioxopiperazine, ICRF-187.
Topics: Animals; Antibiotics, Antineoplastic; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Interactions; Female; Fluorouracil; Heart; Humans; Piperazines; Razoxane | 1987 |
Drug activity and therapeutic synergism in cancer treatment.
Topics: Animals; Antineoplastic Agents; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Female; Fluorouracil; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Melanoma; Mice; Mitomycin; Mitomycins; Neoplasms; Neoplasms, Experimental; Rats; Razoxane; Teniposide | 1982 |
Combination chemotherapy in patients with advanced colorectal carcinoma previously treated with 5-FU.
Topics: Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Nitrosourea Compounds; Piperazines; Razoxane; Rectal Neoplasms; Semustine; Triazines | 1982 |
Long term survival following chemotherapy for carcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Female; Fluorouracil; Humans; Pancreatic Neoplasms; Razoxane | 1980 |
Cardioprotection with ICRF-187 (Cardioxane) in patients with advanced breast cancer having cardiac risk factors for doxorubicin cardiotoxicity, treated with the FDC regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Cyclophosphamide; Doxorubicin; Echocardiography; Electrocardiography; Female; Fluorouracil; Heart; Heart Failure; Humans; Infusions, Intravenous; Lymphatic Metastasis; Middle Aged; Razoxane; Remission Induction; Risk Factors; Stroke Volume; Ventricular Function, Left | 1995 |
[The use of Cardioxan as a cardioprotective agent during antitumor chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiomyopathies; Cardiovascular Agents; Cyclophosphamide; Doxorubicin; Drug Evaluation; Drug Interactions; Female; Fluorouracil; Heart; Humans; Middle Aged; Razoxane; Remission Induction | 1994 |
New drug counters doxorubicin cardiotoxicity; not for use at start of chemotherapy.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Agents; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Heart; Heart Failure; Humans; Razoxane | 1995 |
[Cardioxan as a cardioprotector in antineoplastic chemotherapy].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Agents; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Heart; Heart Failure; Humans; Radionuclide Ventriculography; Razoxane; Treatment Outcome | 1996 |
Delayed administration of dexrazoxane provides cardioprotection against anthracyclines in breast cancer or acute myeloid leukemia.
Topics: Acute Disease; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Heart; Humans; Leukemia, Myeloid; Middle Aged; Razoxane | 1997 |
A new conservative approach to extravasation of anthracyclines with dimethylsulfoxide and dexrazoxane.
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cryotherapy; Cyclophosphamide; Dimethyl Sulfoxide; Edema; Enzyme Inhibitors; Epirubicin; Erythema; Extravasation of Diagnostic and Therapeutic Materials; Female; Fluorouracil; Free Radical Scavengers; Hand; Humans; Hydrocortisone; Infusions, Intravenous; Iron Chelating Agents; Pain; Pain Management; Razoxane; Ulcer | 2001 |
Intrapleural extravasation of epirubicin, 5-fluouracil, and cyclophosphamide, treated with dexrazoxane.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Extravasation of Diagnostic and Therapeutic Materials; Female; Fluorouracil; Humans; Mastectomy, Segmental; Middle Aged; Pleural Cavity; Pleural Effusion; Razoxane; Treatment Outcome | 2006 |
Cardiotoxicity in patients treated with bevacizumab is potentially reversible.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Labeling; Early Termination of Clinical Trials; Epirubicin; Female; Fluorouracil; Heart Failure; Humans; Lymphoma, Large B-Cell, Diffuse; Meta-Analysis as Topic; Paclitaxel; Prednisone; Razoxane; Remission, Spontaneous; Rituximab; Trastuzumab; Vincristine | 2011 |